STAT stories you may have missed

The generic drug industry lost its case challenging a California law banning so-called pay-for-delay agreements. Now they’re eyeing an appeal.

Curious about the biggest market-moving events for biotech this quarter? We’ve got you covered. 

A spate of class actions against top CBD makers could decimate the industry, or it could prompt Washington to act. 

The new year means new drug price hikes. Pharmalot takes readers through what that means. 

Here’s three drug pricing experiments you should watch in 2020. 

The world’s first Ebola vaccine was more than two decades in the making. Here are the key people who made it happen.